We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer (ESD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2010 by National Evidence-Based Healthcare Collaborating Agency.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01132469
First Posted: May 28, 2010
Last Update Posted: May 28, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Evidence-Based Healthcare Collaborating Agency
May 24, 2010
May 28, 2010
May 28, 2010
May 2010
December 2016   (Final data collection date for primary outcome measure)
5-year disease(gastric cancer)-free survival rate after ESD procedure [ Time Frame: 5 years after ESD ]
Same as current
No Changes Posted
  • Short-term result(Histological complete resection,complication) [ Time Frame: within the first 7 days after ESD ]
  • The incidence of reoccurrence and Ectopic foci [ Time Frame: within the first 7 days and 3months, 6months, 1year, 2years, 3years, 4years and 5years after ESD ]
  • The quality of life after ESD [ Time Frame: before and 7 days, 3months, 6months after ESD ]
  • The costs of ESD [ Time Frame: From the admission to discharge ]
  • The safety of ESD procedure [ Time Frame: within the 7 days, 3months, 6months, 1year, 2years, 3years, 4years and 5years after ESD ]
Same as current
Not Provided
Not Provided
 
Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer
Long-term Follow-up After Endoscopic Submucosal Dissection for Early Gastric Cancer
The purpose of this study is to evaluate the safety and clinical effectiveness of ESD(Endoscopic Submucosal Dissection) for early gastric cancer analyzing short-term and long-term results of endoscopic treatment.

Traditionally open-gastrectomy is the standard treatment for gastric cancer without distant metastasis, but high mortality and morbidity, the intense weight loss, food intake difficulties after surgery are fraught, including problems with the drawback of significantly degrading the quality of life. Therefore, a lot of effort to seek the more simple treatment than open gastrectomy has been made, recently the endoscopic treatment for early gastric cancer is the most widely used treatment.

This single-arm, multi-center study enroll early gastric cancer patients after ESD compared with the retrospective control(surgical treatment) group considering the unreality of the randomized clinical trials. In addition, the quality of life assessment by the EORTC C30/STO22 tools before and after ESD procedure in enrolled patients will be performed and the direct cost analysis also will be conducted.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Endoscopic Submucosal Dissection
  • Early Gastric Cancer
  • Multi-center, Single-arm Clinical Trial
  • Historical Control Group
  • Quality of Life and Cost Analysis
Procedure: Endoscopic Submucosal Dissection
5-years follow-up after Endoscopic Submucosal Dissection
Experimental: Endoscopic Submucosal Dissection
Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
Intervention: Procedure: Endoscopic Submucosal Dissection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
1158
June 2017
December 2016   (Final data collection date for primary outcome measure)
  1. ESD GROUP

    Inclusion Criteria:

    • Korean people aged >=20 years
    • Endoscopic Grossly the lesion diameter ≤ 3cm
    • Endoscopic biopsy results: Well-differentiated and moderately differentiated adenocarcinoma
    • No ulcers in lesions
    • Endoscopic biopsy results: In case of gastric cancer, no metastasis in CT test performed before ESD procedure

    Exclusion Criteria:

    • Subject with history of malignant disease in other organs
    • Subject with history of stomach surgery due to peptic ulceration etc.
    • As the cases of an absolute contraindication of general anesthesia; Subject with chronic liver disease over Child score B, Subject with chronic Renal Disease requiring hemodialysis or peritoneal dialysis, Subject with heart failure more than Ⅲ score according to New York Heart Association Classification, Subject with severe systemic diseases such as respiratory disease
    • Subject with Bleeding tendency
    • Pregnant woman or woman with possibility of pregnancy
    • Subject who cann't be obtained informed consent
    • Subject who is unable to follow up for any other reason
  2. Surgery Group(Retrospective data collection)

Inclusion Criteria:

  • Subject with gastric laparoscopy or open-surgery for treatment early gastric cancer during 2002.1.1 ~2004. 12. 31
  • Korean people aged >=20 years
  • Early gastric cancer confirmed by pathology during gastric surgery; Gastric cancer confirmed to the mucosal or submucosal regardless of lymph node metastasis
  • No history of malignant disease in other organs
  • No history of stomach surgery due to peptic ulceration etc.
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01132469
NA09-003
No
Not Provided
Not Provided
Eunhee Shin/General Manager of Pragmatic Clinical Trials Team, National Evidence-based Healthcare Collaborating Agency
National Evidence-Based Healthcare Collaborating Agency
Not Provided
Principal Investigator: Sang-Yong Seol, M.D. Inje University College of Medicine
National Evidence-Based Healthcare Collaborating Agency
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP